Cancer therapeutics deal with Bayer HealthCare could mean $540 million for Compugen
The companies signed a collaboration
and license agreement for R&D and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune
checkpoint regulators